A 24-week, Randomised, Multi-centre, Double-blind, Parallel-group Trial to Investigate the Safety and the Efficacy of NN2000-Mix30 Compared to NN-X14Mix30 NovoRapid30Mix) in Subjects With Type 2 Diabetes Mellitus on a Twice Daily Regimen

Trial Profile

A 24-week, Randomised, Multi-centre, Double-blind, Parallel-group Trial to Investigate the Safety and the Efficacy of NN2000-Mix30 Compared to NN-X14Mix30 NovoRapid30Mix) in Subjects With Type 2 Diabetes Mellitus on a Twice Daily Regimen

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Insulin aspart/insulin protamine aspart (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jun 2009 Actual patient number (126) added as reported by ClinicalTrials.gov.
    • 17 Jun 2009 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top